Burkholderia cepacia complex: A contraindication to lung transplantation in cystic fibrosis?

Transplant Infectious Disease

Volumn 3, Issue 3, 2001, Pages 149-160

  Lipuma, J J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Burkholderia cepacia complex; Cystic fibrosis; Transplantation

Indexed keywords

BACTERIAL VIRULENCE; BACTERIUM ISOLATE; BURKHOLDERIA CEPACIA; CYSTIC FIBROSIS; LUNG INFECTION; LUNG TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SPUTUM; TREATMENT CONTRAINDICATION;

BURKHOLDERIA CEPACIA; BURKHOLDERIA INFECTIONS; CYSTIC FIBROSIS; HUMANS; LUNG TRANSPLANTATION; RISK FACTORS; TREATMENT OUTCOME; VIRULENCE;

EID: 0034864854     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.2001.003003149.x     Document Type: Review

References (137)

1. Burkholderia cepacia. Management issues and new insights
2. Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis
3. Sour skin, a bacterial rot of onion bulbs
4. Necrotizing pneumonitis due to the pseudomonad "eugonic oxidizer-group 1"
5. Pseudomonas cepacia (multivorans) septicaemia in an intensive-care unit
6. Lung abscess due to Pseudomonas cepacia
7. Pseudobacteremia attributed to contamination of povidone-iodine with Pseudomonas cepacia
8. Pseudobacteremia caused by povidone-iodine solution contaminated with Pseudomonas cepacia
9. Nosocomial Pseudomonas cepacia infection associated with chlorhexidine contamination
10. Pseudomonas species bacteremia caused by contaminated normal human serum albumin
11. Pseudomonas cepacia and maltophilia in the cystic fibrosis patient
12. Pseudomonas cepacia in the respiratory flora of patients with cystic fibrosis
13. Antibiotic prophylaxis in cystic fibrosis: Inhaled cephaloridine as an adjunct to oral cloxacillin
14. Pseudomonas cepacia infection in cystic fibrosis: An emerging problem
15. Pseudomonas cepacia colonization in patients with cystic fibrosis: Risk factors and clinical outcome
16. Pseudomonas cepacia colonization among patients with cystic fibrosis. A new opportunist
17. Pseudomonas cepacia: Biology, mechanisms of virulence, epidemiology
18. The epidemiology of Pseudomonas cepacia in patients with cystic fibrosis
19. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis
20. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis
21. DNA fingerprinting by pulsed field gel electrophoresis and ribotyping to distinguish Pseudomonas cepacia isolates from a nosocomial outbreak
22. Transmission of Pseudomonas cepacia among cystic fibrosis patients
23. Burkholderia cepacia respiratory tract acquisition: Epidemiology and molecular characterization of a large nosocomial outbreak
24. Epidemic of Pseudomonas cepacia in an adult cystic fibrosis unit: Evidence of person-to-person transmission
25. Lack of evidence of nosocomial cross-infection by Burkholderia cepacia among Danish cystic fibrosis patients
26. Transmissibility of Pseudomonas cepacia infection in clinic patients and lung-transplant recipients with cystic fibrosis
27. Pseudomonas cepacia
28. Pseudomonas cepacia bacteremia in cystic fibrosis
29. Pseudomonas cepacia: A new pathogen in patients with cystic fibrosis referred to a large centre in the United Kingdom
30. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes
31. Outcome for patients colonized with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic
32. Pseudomonas cepacia in adult cystic fibrosis: Accelerated decline in lung function and increased mortality
33. Pseudomonas cepacia: Pulmonary infection in patients with cystic fibrosis
34. Outcome of Burkholderia (Pseudomonas) cepacia colonization in children with cystic fibrosis following a hospital outbreak
35. Effect of Pseudomonas cepacia colonization on survival and pulmonary function of cystic fibrosis patients
36. Burkholderia cepacia in cystic fibrosis. Variable disease course
37. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria
38. Decreased baseline beta-lactamase production and inducibility associated with increased piperacillin susceptibility of Pseudomonas cepacia isolated from children with cystic fibrosis
39. Treatment of cepacia: In search of the magic bullet
40. Isolation and characterization of dihydrofolate reductase from trimethoprim-susceptible and trimethoprim-resistant Pseudomonas cepacia
41. Nucleotide sequence analysis of a gene from Burkholderia (Pseudomonas) cepacia encoding an outer membrane lipoprotein involved in multiple antibiotic resistance
42. Immunopathogenesis of cystic fibrosis lung disease
43. Pulmonary function, serum markers of inflammation, and IgG antibodies to core lipopolysaccharide of Burkholderia cepacia in adults with cystic fibrosis following colonization with Burkholderia cepacia
44. Antibody response to Burkholderia cepacia in patients with cystic fibrosis colonized with Burkholderia cepacia and Pseudomonas aeruginosa
45. Longitudinal serum IgG response to Pseudomonas cepacia surface antigens in cystic fibrosis
46. Pseudomonas cepacia in inpatients with cystic fibrosis
47. Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia
48. Biological activity of Burkholderia (Pseudomonas) cepacia lipopolysaccharide
49. Lipopolysaccharide (LPS) from Burkholderia cepacia is more active than LPS from Pseudomonas aeruginosa and Stenotrophomonas maltophilia in stimulating tumor necrosis factor alpha from human monocytes
50. Induction of biologically active interleukin-8 from lung epithelial cells by Burkholderia (Pseudomonas) cepacia products
51. Clinical and inflammatory responses in CF patients infected with Pseudomonas aeruginosa and Pseudomonas cepacia
52. Corticosteriod treatment of Burkholderia cepacia septicemia
53. Structurally variant classes of pilus appendage fibers coexpressed from Burkholderia (Pseudomonas) cepacia
54. Cable (cbl) type II pill of cystic fibrosis-associated Burkholderia (Pseudomonas) cepacia: Nucleotide sequence of the cblA major subunit pilin gene and novel morphology of the assembled appendage fibers
55. The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain
56. Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis
57. Invasion and intracellular survival of Burkholderia cepacia
58. Intracellular survival of Burkholderia cepacia complex isolates in the presence of macrophage cell activation
59. Invasion of respiratory epithelial cells by Burkholderia (Pseudomonas) cepacia
60. Inapparent transmission of Pseudomonas (Burkholderia) cepacia among patients with cystic fibrosis
61. Infection with Pseudomonas cepacia in chronic granulomatous disease: Role of nonoxidative killing by neutrophils in host defense
62. The dsbB gene product is required for protease production by Burkholderia cepacia
63. A nonhemolytic phospholipase C from Burkholderia cepacia
64. In vitro analysis of roles of a disulfide bridge and a calcium binding site in activation of Pseudomonas sp. strain KWI-56 lipase
65. Burkholderia cepacia produces a hemolysin that is capable of inducing apoptosis and degranulation of mammalian phagocytes
66. Siderophore production by cystic fibrosis isolates of Burkholderia cepacia
67. Identification of a siderophore receptor required for ferric ornibactin uptake in Burkholderia cepacia
68. Virulence factors of Burkholderia cepacia
69. Structural elucidation of a novel exopolysaccharide produced by a mucoid clinical isolate of Burkholderia cepacia. Characterization of a trisubstituted glucuronic acid residue in a heptasaccharide repeating unit
70. Molecular typing and exopolysaccharide biosynthesis of Burkholderia cepacia isolates from a Portuguese cystic fibrosis center
71. A melanin pigment purified from an epidemic strain of Burkholderia cepacia attenuates monocyte respiratory burst activity by scavenging superoxide anion
72. Quorum sensing in Burkholderia cepacia: Identification of the LuxRI homologs CepRI
73. Heart-lung transplantation: Successful therapy for patients with pulmonary vascular disease
74. Lung transplantation for cystic fibrosis
75. Should patients with cystic fibrosis infected with Burkholderia cepacia undergo lung transplantation?
76. Infectious complications of lung transplantation. Impact of cystic fibrosis
77. Heart-lung transplantation in cystic fibrosis - Overview
78. Successful heart-lung transplantation for cystic fibrosis
79. The role of heart and lung transplantation in the treatment of cystic fibrosis
80. Heart and lung transplantation for terminal cystic fibrosis
81. Heart-lung transplantation for cystic fibrosis and subsequent domino heart transplantation
82. Cystic fibrosis treated with heart-lung transplantation: North America results
83. Technique of successful clinical double lung transplantation
84. Bilateral lung transplantation for cystic fibrosis
85. Double-lung transplantation for cystic fibrosis
86. Pulmonary transplantation. Early and late results
87. Lung transplantation for cystic fibrosis: Effective and durable therapy in a high-risk group
88. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease
89. Experience with pediatric lung transplantation
90. Pseudomonas cepacia in lung transplant recipients with cystic fibrosis
91. A decade of lung transplantation
92. Infections in patients with cystic fibrosis following lung transplantation
93. Double-lung transplantation in mechanically ventilated patients with cystic fibrosis
94. Complications of pediatric lung and heart-lung transplantation
95. Post-transplantation survival of cystic fibrosis patients infected with Pseudomonas cepacia
96. The potential of nosocomial transmission of Pseudomonas cepacia exists at cardiopulmonary transplant centers
97. Ribotype analysis of Pseudomonas cepacia from cystic fibrosis treatment centers
98. Burkholderia cepacia in cystic fibrosis
99. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome
100. Infection with Burkholderia cepacia in cystic fibrosis
101. Survival following lung transplantation of cystic fibrosis patients colonized with Burkholderia cepacia
102. Pseudomonas cepacia empyema necessitatis after lung transplantation in two patients with cystic fibrosis
103. Subdural empyema due to Burkholderia cepacia: An unusual complication after lung transplantation for cystic fibrosis
104. Bronchiolitis obliterans organizing pneumonia (BOOP) in lung transplant recipients
105. Pleural complications in lung transplant recipients
106. Nucleid acid homologies in the genus Pseudomonas
107. Proposal of Burkholderia gen. nov. and transfer of seven species of the genus Pseudomonas homology group II to the new genus, with the type species Burkholderia cepacia
108. Transfer of two Burkholderia and an Alcaligenes species to Ralstonia gen. nov
109. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov
110. 2-fixing isolates from rice in Vietnam
111. Identification and population structure of Burkholderia stabilis sp. nov. (formerly Burkholderia cepacia Genomovar IV)
112. Burkholderia cepacia genomovar VI, a new member of the Burkholderia cepacia complex isolated from cystic fibrosis patients
113. Burkholderia ambifaria sp. nov., a novel member of the Burkholderia cepacia complex comprising biocontrol and cystic fibrosis-related isolates
114. Linkage analysis of geographic and clinical clusters in Pseudomonas cepacia infections by multilocus enzyme electrophoresis and ribotyping
115. Type characterization and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland
116. Population density of the biocontrol agent Burkholderia cepacia AMMDR1 on four pea cultivars
117. Detection, recovery and identification of Burkholderia cepacia from the natural environment
118. PCR ribotyping and endonuclease subtyping in the epidemiology of Burkholderia cepacia infection
119. Transmission and prevalence of Burkholderia cepacia in Welsh cystic fibrosis patients
120. Genetic relatedness of Burkholderia (Pseudomonas) cepacia isolates from five cystic fibrosis centers in Michigan
121. Biochemical and genetic characteristics of epidemic strains of Burkholderia cepacia with cystic fibrosis
122. Differentiation of Burkholderia species by PCR-restriction fragment length polymorphism analysis of the 16S rRNA gene and application to cystic fibrosis isolates
123. Cross infection between cystic fibrosis patients colonized with Burkholderia cepacia
124. Burkholderia cepacia epidemiology and pathogenesis: Implications for infection control
125. Molecular epidemiology of Burkholderia cepacia in two Australian cystic fibrosis centres
126. Pseudomonas cepacia in the sputum of cystic fibrosis patients
127. Lung transplantation for cystic fibrosis; the effect of B. cepacia genomovars on post-transplant outcomes
128. Development of rRNA-based PCR assays for identification of Burkholderia cepacia complex isolates recovered from cystic fibrosis patients
129. Discrimination of Burkholderia multivorans and Burkholderia vietnamiensis from Burkholderia cepacia genomovars I, III, and IV by PCR
130. DNA-based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia Genomovars I and III
131. Misidentification of Burkholderia cepacia in US cystic fibrosis treatment centers. An analysis of 1,051 recent sputum isolates
132. Utility of commercial systems for identification of Burkholderia cepacia complex from cystic fibrosis sputum culture
133. Ribotype stability of serial pulmonary isolates of Pseudomonas cepacia
134. Comparison of culture and PCR for detection of Burkholderia cepacia in sputum samples of patients with cystic fibrosis